美国小企业创新药物研发促进计划及对我国的启示  

The U.S. Promoting Plan of Innovation Drug Research and Development for Small Business and Its Enlightenment to China

作　　者：伍琳[1] 陈永法[1] 

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198

出　　处：《中国医药工业杂志》2017年第9期1383-1389,共7页Chinese Journal of Pharmaceuticals

基　　金：国家社会科学基金重大项目(15ZDB167);国家社会科学基金项目(15BZZ052);江苏省普通高校研究生科研创新计划资助项目(KYCX17_0736)

摘　　要：小企业历来被视为美国经济增长和社会进步的引擎,在SBIR/STTR计划逾30年的高效资助下更是逐渐成为美国创新药物研发的核心驱动力。本文系统剖析了SBIR/STTR计划的资助流程和创新促进机制,发现其显著提高了小企业研发创新药物的数量和占比,并使得产学研合作创新关系更为紧密。基于我国医药产业发展实际,建议从设立专门的监管服务机构、实行分阶段竞争性资助和培育协同创新环境三个方面,完善我国小企业创新药物研发的激励管理。Small business have long been seen as the engine of economic growth and social progress in the United States, and gradually become the key driver of innovative drug research and development in U.S. under the efficient financing of SBIR/STTR program for over thirty years. This paper systematically analyzed the funding process and innovation promotion mechanism of SBIR/STTR program, and found that it significantly improved the quantity and proportion of innovative drugs in small enterprises, and made the innovation relationship of industry-university- research collaboration more closely. Based on the actual development of China＇s pharmaceutical industry, it is suggested that to improve the incentive management of innovation drug research and development for small business in China, we need to establish the specialized regulatory service agencies, implement the phased competitive financing and cultivate collaborative innovation environment.

关 键 词：小企业 创新药物 协同管理 产学研合作 

分 类 号：R95[医药卫生—药学]